Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.69 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | PIM1 | P11309 | 1/20 | 0.56 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.56 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.56 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.56 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.56 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3759135 | 1.00 | PNP (0.69) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL3766539 | 1.00 | PNP (0.69) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL3766542 | 1.00 | PNP (0.69) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL13058797 | 0.87 | PNP (0.53) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL29820266 | 0.87 | HIF1A (0.58) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL311622 | 0.87 | HIF1A (0.58) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL311621 | 0.87 | HIF1A (0.58) | PNPLMNATP53HTTPDE4D | |
| Deoxyadenosine SCHEMBL23982174 | 0.84 | HIF1A (0.71) | PNPLMNATP53HTTPDE4D | |
| Deoxyadenosine SCHEMBL193181 | 0.84 | HIF1A (0.71) | PNPLMNATP53HTTPDE4D | |
| Deoxyadenosine SCHEMBL19877 | 0.84 | HIF1A (0.71) | PNPLMNATP53HTTPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287034-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH INC (US) | 2023-09-14 | — | — | US | disclosed |
| US-11597746-B2 | Cyclic dinucleotides as sting agonists | JANSSEN BIOTECH, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20210277046-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-09 | — | — | US | disclosed |
| EP-3823976-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | Janssen Biotech, Inc. (US) | 2021-05-26 | — | — | EP | disclosed |
| CN-112424212-A | Cyclic dinucleotides as STING agonists | 詹森生物科技公司 | 2021-02-26 | — | — | CN | disclosed |
| WO-2020016782-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH, INC. (US) | 2020-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287034-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | STING1, CGAS, IFNAR1 | PNP 313/4885LMNA 659/4885TP53 1210/4885 |
| US-20210277046-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | STING1, CGAS, IFNAR1 | PNP 319/4885LMNA 653/4885TP53 1230/4885 |
| US-11597746-B2 | Cyclic dinucleotides as sting agonists | STING1, CGAS, IFNAR1 | PNP 319/4885LMNA 653/4885TP53 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.